March, 31 2016, 09:45am EDT
Lawsuit Challenges FDA's Approval of Genetically Engineered Salmon
Coalition of fishing, consumer, and environmental groups say first-ever approval of laboratory-created food animal violated laws and ignored risks to wild salmon and fishing communities
SAN FRANCISCO, Calif.
A broad coalition of environmental, consumer, and commercial and recreational fishing organizations today sued the U.S. Food and Drug Administration for approving the first-ever genetically engineered -- GE -- food animal, an Atlantic salmon engineered to grow quickly. The man-made salmon was created by AquaBounty Technologies, Inc. with DNA from three fish: Atlantic salmon, Pacific king salmon, and Arctic ocean eelpout. This marks the first time any government in the world has approved a GE animal for commercial sale and consumption.
The plaintiff coalition, jointly represented by legal counsel from Center for Food Safety and Earthjustice, includes Pacific Coast Federation of Fishermen's Associations, Institute for Fisheries Resources, Golden Gate Salmon Association, Kennebec Reborn, Friends of Merrymeeting Bay, Ecology Action Centre, Food & Water Watch, Center for Biological Diversity, Friends of the Earth, Cascadia Wildlands, and Center for Food Safety.
In approving the GE salmon, FDA determined it would not require labeling of the GE fish to let consumers know what they are buying, which led Congress to call for labeling in the 2016 omnibus spending bill. FDA's approval also ignored comments from nearly 2 million people opposed to the approval because the agency failed to analyze and prevent the risks to wild salmon and the environment, as well as fishing communities, including the risk that GE salmon could escape and threaten endangered wild salmon stocks.
AquaBounty's GE salmon will undertake a 5,000-mile journey to reach U.S. supermarkets. The company plans to produce the GE salmon eggs on Prince Edward Island, Canada. The GE salmon will then be grown to market-size in a facility in Panama, processed into fillets, and shipped to the U.S. for sale. That complicated scheme is only for the initial approval, however. AquaBounty has publicly announced plans to ultimately grow its GE fish in the U.S. rather than Panama, and sell it around the world. Despite this, FDA's approval only considered the current plans for the far-flung facilities in Canada and Panama, leaving the risk of escape and contamination of U.S. salmon runs unstudied.
The lawsuit challenges FDA's claim that it has authority to approve and regulate GE animals as "animal drugs" under the 1938 Federal Food, Drug, and Cosmetic Act. Those provisions were meant to ensure the safety of veterinary drugs administered to treat disease in livestock and were not intended to address entirely new GE animals that can pass along their altered genes to the next generation. The approval of the GE salmon opens the door to other genetically engineered fish and shellfish, as well as chickens, cows, sheep, goats, rabbits and pigs that are reportedly in development.
The lawsuit also highlights FDA's failure to protect the environment and consult wildlife agencies in its review process, as required by federal law. U.S. Atlantic salmon, and many populations of Pacific salmon, are protected by the Endangered Species Act and in danger of extinction. Salmon is a keystone species and unique runs have been treasured by residents for thousands of years. Diverse salmon runs today sustain thousands of American fishing families, and are highly valued in domestic markets as a healthy, domestic, "green" food.
When GE salmon escape or are accidentally released into the environment, the new species could threaten wild populations by mating with endangered salmon species, outcompeting them for scarce resources and habitat, and/or introducing new diseases. Studies have shown that there is a high risk for GE organisms to escape into the natural environment, and that GE salmon can crossbreed with native fish. Transgenic contamination has become common in the GE plant context, where contamination episodes have cost U.S. farmers billions of dollars over the past decade. In wild organisms like fish, it could be even more damaging.
The world's preeminent experts on GE fish and risk assessment, as well as biologists at U.S. wildlife agencies charged with protecting fish and wildlife heavily criticized the FDA decision for failing to evaluate these impacts. FDA ignored their concerns in the final approval.
Statements from counsel and plaintiff coalition:
"FDA's decision is as unlawful as it is irresponsible," said George Kimbrell, senior attorney for Center for Food Safety and co-counsel for the plaintiffs. "This case is about protecting our fisheries and ocean ecosystems from the foreseeable harms of the first-ever GE fish, harms FDA refused to even consider, let alone prevent. But it's also about the future of our food: FDA should not, and cannot, responsibly regulate this GE animal, nor any future GE animals, by treating them as drugs under a 1938 law."
"FDA has not answered crucial questions about the environmental risks posed by these fish or what can happen when these fish escape," said Earthjustice attorney Brettny Hardy and co-counsel for plaintiffs. "We need these answers now and the FDA must be held to a higher standard. We are talking about the mass production of a highly migratory GE fish that could threaten some of the last remaining wild salmon on the planet. This isn't the time to skimp on analysis and simply hope for the best."
"Atlantic salmon populations including our endangered Gulf of Maine fish are hanging on by a thread- they can't afford additional threats posed by GE salmon," said Ed Friedman from Friends of Merrymeeting Bay, one of the parties who successfully petitioned to classify most Maine Atlantic salmon as endangered. "The law requires agencies like FDA, who aren't fisheries biologists, to get review and approval from scientists with that expertise. FDA's refusal to do this before allowing commercialization of GE salmon is not only irresponsible, it violates the law."
"On Prince Edward Island and across Atlantic Canada, indigenous peoples, anglers and community groups are working hard to protect and restore endangered salmon populations and rivers. Genetic contamination threatens all this work and in return there is little or no economic benefit to the region," said Mark Butler, policy director at Ecology Action Centre in Nova Scotia.
There's never been a farmed salmon that hasn't eventually escaped into the natural environment. Why should we believe that long term, these frankenfish won't be the same?" asked Golden Gate Salmon Association executive director John McManus.
"Once they escape, you can't put these transgenic fish back in the bag. They're manufactured to outgrow wild salmon, and if they cross-breed, it could have irreversible impacts on the natural world," said Dune Lankard, a salmon fisherman and the Center for Biological Diversity's Alaska representative. "This kind of dangerous tinkering could easily morph into a disaster for wild salmon that will be impossible to undo."
"FDA's action threatens and disrespects the wild salmon ecosystems, cultures and industries that are treasured here in the Pacific Northwest and Alaska," said Gabriel Scott, Alaska legal director for Cascadia Wildlands. "These folks think a salmon is just a packet of protein, but we in Salmon Nation know better. From Alaska to California, Americans are intimately related with diverse runs of salmon and we've learned their unique attributes and incredible value. We've worked very hard to be good stewards of our natural heritage, and refuse to allow that to be undone by one company's irresponsible experiment."
"The FDA has failed to adequately examine the risks associated with transgenic salmon," said Wenonah Hauter, executive director of Food & Water Watch. "The long term effects of people eating genetically modified foods have never been adequately addressed--and this GE salmon is no exception. This fish is unnecessary, so why take the risk?"
"It's clear that the market has rejected GE salmon despite FDA's reckless approval," said Dana Perls, food and technology campaigner for Friends of the Earth. "Major retailers including Costco, Safeway and Kroger won't sell it and polls show the vast majority of people don't want to eat it. Yet under this approval it won't be labeled, violating our fundamental right to know what we are feeding our families."
For more information, visit:
https://www.centerforfoodsafety.org/issues/309/ge-fish or
www.biologicaldiversity.org/campaigns/ge_seafood/
Center for Food Safety's mission is to empower people, support farmers, and protect the earth from the harmful impacts of industrial agriculture. Through groundbreaking legal, scientific, and grassroots action, we protect and promote your right to safe food and the environment. CFS's successful legal cases collectively represent a landmark body of case law on food and agricultural issues.
(202) 547-9359LATEST NEWS
Nancy Pelosi 'Making Calls' to Undermine AOC's Bid for Top Oversight Role
"It is so infantilizing to the House leadership to have a B team of octagenarians scheming behind their backs and aiming directly at their most promising young talent," said one progressive journalist.
Dec 13, 2024
Progressives on Thursday were frustrated by reports that former House Speaker Nancy Pelosi is using her considerable influence on Capitol Hill to undermine Rep. Alexandria Ocasio-Cortez's bid to become the top Democrat on the powerful committee that could launch investigations into the Trump White House in the coming years.
As Common Dreamsreported last week, Pelosi (D-Calif.) has publicly indicated that she is supporting Rep. Gerry Connolly (D-Va.) to succeed Rep. Jamie Raskin (D-Md.) as ranking member on the House Committee on Oversight and Accountability when the 119th Congress begins in January.
But Punchbowl Newsreported that Pelosi—well-known for her relentless and often successful efforts to whip votes within the Democratic caucus—is also "making calls" to other Democratic lawmakers on behalf of Connolly.
The outlet reported that the former House speaker is "actively working to tank" the candidacy of Ocasio-Cortez (D-N.Y.), with whom she has had a rocky relationship at times as the progressive Democrat has pushed the party to embrace far-reaching reforms on climate, immigration, and other issues.
Both Connolly and Ocasio-Cortez believe they have the votes to win the ranking member position. Ocasio-Cortez is a close ally of Raskin, who named her vice ranking member in the current Congress, but the Maryland lawmaker, who is expected to succeed Rep. Jerrold Nadler (D-N.Y.) as ranking member of the House Judiciary Committee, has not publicly endorsed either candidate.
The Democratic Steering and Policy Committee, which has close ties to Minority Leader Hakeem Jeffries (D-N.Y.), is expected to make a recommendation for the ranking member role, after which the entire Democratic caucus will vote.
The centrist New Democrat Coalition endorsed Connolly on Friday, while a House Democrat told Axios that Ocasio-Cortez "has pretty much the entire [Oversight] Committee with her."
The Congressional Progressive Caucus announced its endorsement of Ocasio-Cortez on Friday, with Chair Pramila Jayapal (D-Wash.) and Chair-elect Greg Casar (D-Texas) arguing the congresswoman's "fearless advocacy leading the Oversight Committee will help ensure Democrats retake the House in 2026."
"Throughout her tenure on Oversight, Rep. Ocasio-Cortez has been a powerful voice for working people," said Jayapal and Casar. "She has wielded her seat on this committee to hold CEOs, Wall Street, and mega-corporations accountable to the American people. Her investigations that pressured Big Pharma to bring down the price of PrEP and other critical medications are just one example of her influential leadership and commitment to everyday people."
As Axios reported, several older longtime members are facing challenges for leadership roles from the party's younger generation. Ocasio-Cortez, 35, was the youngest woman ever elected to Congress when she won her election in 2018, and is an outspoken member of the progressive "Squad" which advocates for policies such as Medicare for All and has reportedly angered Pelosi in the past with its embrace of calls to "abolish" Immigration and Customs Enforcement (ICE).
"Many members are concerned about [the] precedent these races are setting," a senior House Democrat told Axios regarding the progressive contests with members like Connolly, who is 74.
Ryan Grim of Drop Site News said Pelosi's lobbying against Ocasio-Cortez "reeks of pettiness."
David Dayen, executive editor of The American Prospect, said the new reporting shows Pelosi attempting to act as a "puppet master."
"It is so infantilizing to the House leadership to have a B team of octagenarians scheming behind their backs and aiming directly at their most promising young talent," said Dayen.
Ocasio-Cortez wrote to colleagues last week to announce her bid for the ranking member position, highlighting her involvement in derailing Republican efforts to "weaponize the committee's investigatory power for partisan purposes" and pledging to balance the Oversight Committee's focus on President-elect Donald Trump's actions with fighting to better the lives of working Americans.
If Democrats win back control of the House in 2026, the committee would be empowered to launch investigations into the incoming Trump administration and would have subpoena power.
Keep ReadingShow Less
Warning of 'Unprecedented Risks,' Scientists Say Mirror Bacteria 'Should Not Be Created'
"Our analysis suggests that mirror bacteria could broadly evade many immune defenses of humans, animals, and plants," according to a group of 38 scientists, including multiple Nobel Prize winners.
Dec 13, 2024
Dozens of scientists are calling in no uncertain terms for a halt on research to create "mirror life," particularly "mirror bacteria" that could "pose ecological risks" and possibly cause "pervasive lethal infections in a substantial fraction of the plant and animal species, including humans."
The group of 38 scientists, who include Nobel laureates and other experts, addressed research into "mirror life"—mirror-image biological molecules—in a piece of commentary published in the journal Science published Friday, which accompanied a technical report that was released earlier in December.
One of the scientists, synthetic biologist Kate Adamala at the University of Minnesota, was working on creating a mirror cell but "changed track last year" after studying the risks, according to the Guardian.
"We should not be making mirror life," she told the outlet. "We have time for the conversation. And that's what we were trying to do with this paper, to start a global conversation."
To that end, the authors of the commentary plan to convene discussions on the risks of mirror life and related topics in 2025, with the hope that "society at large will take a responsible approach to managing a technology that might pose unprecedented risks."
The ability to create mirror life is likely over a decade away and would require sizable investment and technical progress, meaning the world has the opportunity to "preempt risks before they are realized," according to the scientists.
When broken down into simple terms, mirror life sounds like something out of science fiction. All the biomolecules that constitute life have a "handedness" to them—"right-handed" nucleotides make up DNA and RNA, and proteins are formed from "left-handed" amino acids.
"So when we're talking about mirror-image life, it's kind of like a 'what if' experiment: What if we constructed life with right-handed proteins instead of left-handed proteins? Something that would be very, very similar to natural life, but doesn't exist in nature. We call this mirror-image life or mirror life," explained to Michael Kay, a professor of biochemistry at University of Utah's medical school.
Some scientists like Kay are interested in the medical possibilities of mirror-image therapeutics—which Kay says holds potential for treating chronic illness in a more cost-effective way—but both he and the authors of the recently published commentary are concerned about the potential threats posed by mirror bacteria.
"Our analysis suggests that mirror bacteria could broadly evade many immune defenses of humans, animals, and plants. Chiral interactions, which are central to immune recognition and activation in multicellular organisms, would be impaired with mirror bacteria," according to the scientists.
Essentially, as Kay puts it, it’s unlikely that mirror bacteria would be subject to the same constraints as regular bacteria, such as the human immune system or antibiotics.
The scientists warn that further developing this research could open a Pandora's box: "Unless compelling evidence emerges that mirror life would not pose extraordinary dangers, we believe that mirror bacteria and other mirror organisms, even those with engineered biocontainment measures, should not be created."
The authors argue that scientific research with the goal of creating mirror bacteria should not be allowed, and that potential funders should not support work related to mirror bacteria.
Keep ReadingShow Less
In Wake of Killing, UnitedHealth CEO Admits 'No One Would Design a System Like the One We Have'
One critic said UnitedHealth Group chief executive Andrew Witty should "resign and then dedicate every dollar he has to dismantling the current system brick by brick and building one based on public health in its stead."
Dec 13, 2024
UnitedHealth Group CEO Andrew Witty wrote in a New York Times op-ed Friday that the for-profit U.S. healthcare system "does not work as well as it should" and that "no one would design a system like the one we have," admissions that came as his industry faced a torrent of public anger following the murder of UnitedHealthcare's chief executive.
Witty declared that his firm, the parent company of UnitedHealthcare and the nation's largest private insurer, is "willing to partner with anyone, as we always have—healthcare providers, employers, patients, pharmaceutical companies, governments, and others—to find ways to deliver high-quality care and lower costs."
But critics didn't buy Witty's expressed commitment to reforming an industry that his company has helped shape and profited from massively. Witty was the highest-paid healthcare executive in the U.S. last year, and 40% of the private insurance industry's total profit since the passage of the Affordable Care Act has flowed to UnitedHealth Group.
"It is (barely) true that UnitedHealth didn't design the U.S. system of corporate insurance, which kills tens of thousands of people a year through denial of care," Alex Lawson, executive director of the progressive advocacy group Social Security Works, told Common Dreams. "But they certainly have perfected it and turned it into a medical murder apparatus at industrial scale. They not only block all attempts to change the system in the direction of public health, they bribe and bully with their billions in blood money to make it even crueler."
"Andrew Witty is the high priest of the temple to Moloch and Mammon, murder and money," Lawson added. "And there is no way for him to wash his hands of it, except perhaps to resign and then dedicate every dollar he has to dismantling the current system brick by brick and building one based on public health in its stead."
"Medicare for All is the only proposal on the table capable of delivering universal, continuous coverage for everyone, while also securing the efficiency and savings only possible through the elimination of private insurance."
While publicly pledging to cooperate with reform efforts, Witty has defended his company's care denials in private and urged his employees not to engage with media outlets in the aftermath of Thompson's murder.
Contrary to Witty's depiction of his company in his Times op-ed, UnitedHealth has historically been an aggressive opponent of reform efforts aimed at mitigating the harms of for-profit insurance and building public alternatives. The Leverreported in 2021 that UnitedHealth Group "held a webinar to pressure its rank-and-file employees to mobilize against efforts in Connecticut to create a state-level public health insurance option."
At the national level, UnitedHealth has spent over $5.8 million this year lobbying the federal government, according to OpenSecrets.
Witty, who was born in a country with a public healthcare system, did not detail the kinds of reforms he would support in his op-ed Friday, but it's clear he would oppose a transition to a single-payer system such as Medicare for All, which would effectively abolish private health insurance and provide coverage to all Americans for free at the point of service—and at a lower total cost than the status quo.
In a column for The Nation on Friday, writer Natalie Shure argued that "the appalling amount of resources and energy we put into maintaining the existence of health insurance is wasted on an industry with no social value whatsoever."
"You could eliminate every one of these corporations tomorrow and build a system without them that works better, for less money, and with less hassle," Shure wrote. "Other countries already have systems like this. Medicare for All is the only proposal on the table capable of delivering universal, continuous coverage for everyone, while also securing the efficiency and savings only possible through the elimination of private insurance."
"None of that means that murder is justified or useful," Shure added. "But anger can be. Some politicians, from Bernie Sanders, to Elizabeth Warren, to Alexandria Ocasio-Cortez, have begun to make public statements ascribing the reaction to Brian Thompson's murder to widespread fury over the health insurance industry. The next step is to harness it, and to build something new."
Keep ReadingShow Less
Most Popular